Cargando…

Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy

The aim of this study was to further elucidate the activity of the hypothalamo–pituitary–adrenal (HPA) axis in patients with malignancy and to correlate this with the size of the adrenal glands. Fourteen patients with a variety of malignancies were studied prior to receiving cytotoxic chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, P J, Sohaib, S A, Trainer, P J, Lister, T A, Besser, G M, Reznek, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363134/
https://www.ncbi.nlm.nih.gov/pubmed/10468302
http://dx.doi.org/10.1038/sj.bjc.6690603
_version_ 1782153628817031168
author Jenkins, P J
Sohaib, S A
Trainer, P J
Lister, T A
Besser, G M
Reznek, R
author_facet Jenkins, P J
Sohaib, S A
Trainer, P J
Lister, T A
Besser, G M
Reznek, R
author_sort Jenkins, P J
collection PubMed
description The aim of this study was to further elucidate the activity of the hypothalamo–pituitary–adrenal (HPA) axis in patients with malignancy and to correlate this with the size of the adrenal glands. Fourteen patients with a variety of malignancies were studied prior to receiving cytotoxic chemotherapy. During routine staging computerized tomographic (CT) scans, the size of the body, medial and lateral limbs of the adrenal glands were measured and compared with those of a normal group of patients studied previously. Measurements of 09:00 h serum cortisol and plasma adrenocorticotropic hormone (ACTH) levels were made before and after the administration of dexamethasone (0.5 mg 6-hourly for 48 h) in addition to the peak cortisol response to i.v corticotropin releasing hormone (CRH). Overall, patients with malignancy had significantly larger adrenal glands than patients without malignancy; those with non-haematological malignancies had larger glands than patients with haematological malignancies. Following dexamethasone to suppress circulating cortisol levels, nine patients (64%) demonstrated abnormal resistance with cortisol levels > 50 nmol l(−1): mean value 294 nmol l(−1) (range 67–1147). Those patients who failed to suppress after dexamethasone had significantly larger adrenal glands than those that did suppress and tended to have non-haematological malignancies. ACTH levels were undetectable or low in three patients in whom it was measured and who did not suppress with dexamethasone. Following CRH, the cortisol levels were highest (823 and 853 nmol l(−1)) in two of these patients. Malignancy is associated with diffuse enlargement of the adrenal glands and resistance to dexamethasone-induced suppression of the HPA axis, which is not due to ectopic ACTH secretion. This disturbance of the normal control of the HPA axis is unexplained and its functional significance remains uncertain. © 1999 Cancer Research Campaign
format Text
id pubmed-2363134
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23631342009-09-10 Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy Jenkins, P J Sohaib, S A Trainer, P J Lister, T A Besser, G M Reznek, R Br J Cancer Regular Article The aim of this study was to further elucidate the activity of the hypothalamo–pituitary–adrenal (HPA) axis in patients with malignancy and to correlate this with the size of the adrenal glands. Fourteen patients with a variety of malignancies were studied prior to receiving cytotoxic chemotherapy. During routine staging computerized tomographic (CT) scans, the size of the body, medial and lateral limbs of the adrenal glands were measured and compared with those of a normal group of patients studied previously. Measurements of 09:00 h serum cortisol and plasma adrenocorticotropic hormone (ACTH) levels were made before and after the administration of dexamethasone (0.5 mg 6-hourly for 48 h) in addition to the peak cortisol response to i.v corticotropin releasing hormone (CRH). Overall, patients with malignancy had significantly larger adrenal glands than patients without malignancy; those with non-haematological malignancies had larger glands than patients with haematological malignancies. Following dexamethasone to suppress circulating cortisol levels, nine patients (64%) demonstrated abnormal resistance with cortisol levels > 50 nmol l(−1): mean value 294 nmol l(−1) (range 67–1147). Those patients who failed to suppress after dexamethasone had significantly larger adrenal glands than those that did suppress and tended to have non-haematological malignancies. ACTH levels were undetectable or low in three patients in whom it was measured and who did not suppress with dexamethasone. Following CRH, the cortisol levels were highest (823 and 853 nmol l(−1)) in two of these patients. Malignancy is associated with diffuse enlargement of the adrenal glands and resistance to dexamethasone-induced suppression of the HPA axis, which is not due to ectopic ACTH secretion. This disturbance of the normal control of the HPA axis is unexplained and its functional significance remains uncertain. © 1999 Cancer Research Campaign Nature Publishing Group 1999-08 /pmc/articles/PMC2363134/ /pubmed/10468302 http://dx.doi.org/10.1038/sj.bjc.6690603 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Jenkins, P J
Sohaib, S A
Trainer, P J
Lister, T A
Besser, G M
Reznek, R
Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
title Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
title_full Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
title_fullStr Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
title_full_unstemmed Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
title_short Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
title_sort adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363134/
https://www.ncbi.nlm.nih.gov/pubmed/10468302
http://dx.doi.org/10.1038/sj.bjc.6690603
work_keys_str_mv AT jenkinspj adrenalenlargementandfailureofsuppressionofcirculatingcortisolbydexamethasoneinpatientswithmalignancy
AT sohaibsa adrenalenlargementandfailureofsuppressionofcirculatingcortisolbydexamethasoneinpatientswithmalignancy
AT trainerpj adrenalenlargementandfailureofsuppressionofcirculatingcortisolbydexamethasoneinpatientswithmalignancy
AT listerta adrenalenlargementandfailureofsuppressionofcirculatingcortisolbydexamethasoneinpatientswithmalignancy
AT bessergm adrenalenlargementandfailureofsuppressionofcirculatingcortisolbydexamethasoneinpatientswithmalignancy
AT reznekr adrenalenlargementandfailureofsuppressionofcirculatingcortisolbydexamethasoneinpatientswithmalignancy